- 0.6Impact Factor
- 22 daysTime to First Decision
Reports, Volume 4, Issue 1
March 2021 - 8 articles
Cover Story: The immune system has complementary functions, defending the organism from bacteria, viruses, or tumor cells (immune response), but also following a narrow line, it identifies and respects its own structures. For this immunological tolerance, there are key points such as CTLA-4 or PD-1 that modulate the activation of the immune system. Blocking these pathways with Tremelimumab (anti-CTLA-4 antibody) or Durvalumab (anti-PD-L1 antibody), immune response against cancer is boosted, but autoimmune diseases are frequently triggered by breaking previous immune tolerance as adverse events. View this paper
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Articles
There are no articles in this issue yet.
Get Alerted
Add your email address to receive forthcoming issues of this journal.
Reports - ISSN 2571-841XCreative Common CC BY license